Company Filing History:
Years Active: 1988-1997
Title: Harlan B Long: Innovator in Recombinant DNA Technology
Introduction
Harlan B Long is a notable inventor based in Carmel, IN (US). He has made significant contributions to the field of biotechnology, particularly in the development of insulin analogs and IGF-1 superagonists. With a total of 4 patents to his name, Long's work has had a profound impact on therapeutic applications in diabetes treatment.
Latest Patents
One of Long's latest patents focuses on IGF-1 superagonists. This invention provides two-chain IGF-1 superagonists that are derivatives of the naturally occurring single-chain IGF-1, featuring an abbreviated C domain. The invention also includes synthetic and semi-synthetic DNA sequences, recombinant DNA vectors, and transformed host cells that are useful in the recombinant production of these analogs. Additionally, it offers pharmaceutical formulations comprising these IGF-1 analogs and methods for their therapeutic applications. Another significant patent involves novel molecules derived from proinsulin components using recombinant DNA technology. These molecules possess insulin-like activity and are particularly useful for treating non-insulin dependent diabetes mellitus. The invention outlines a method for producing insulin through these compounds as intermediates.
Career Highlights
Harlan B Long is currently associated with Eli Lilly and Company, a leading pharmaceutical firm known for its innovative contributions to healthcare. His work at Eli Lilly has allowed him to focus on groundbreaking research in diabetes treatment and recombinant DNA technology.
Collaborations
Long has collaborated with esteemed colleagues such as Richard Dennis DiMarchi and Rama M Belagaje. These partnerships have further enhanced the scope and impact of his research in the field.
Conclusion
Harlan B Long's contributions to biotechnology, particularly in the development of insulin analogs and IGF-1 superagonists, highlight his role as a significant inventor in the industry. His work continues to influence therapeutic approaches to diabetes and showcases the importance of innovation in healthcare.